Xylo Bio Dosed First Patients in Phase 1 Trial of XYL-1001 for Depression
Image
Boston – September 17, 2026 -- Xylo Bio has dosed the first participants in a Phase 1 clinical trial of XYL-1001, a selective 5-HT2A receptor agonist targeting major depressive disorder (MDD), marking the company's transition to a clinical-stage biotechnology organization.
Phase 1 trial spans single and multiple ascending dose cohorts in Australia
The randomized, double-blind, placebo-controlled study is evaluating safety, tolerability, pharmacokinetics, and pharmacodynamic activity of XYL-1001 in healthy volunteers. The trial design incorporates translational biomarkers intended to characterize pharmacodynamic engagement and inform future clinical development decisions.